Bond Celgene Corp 3.875% ( US151020AS39 ) in USD

Issuer Celgene Corp
Market price 110.64 %  ▲ 
Country  United States
ISIN code  US151020AS39 ( in USD )
Interest rate 3.875% per year ( payment 2 times a year)
Maturity 14/08/2025 - Bond has expired



Prospectus brochure in PDF format

Minimal amount 2 000 USD
Total amount 2 500 000 000 USD
Cusip 151020AS3
Standard & Poor's ( S&P ) rating A+ ( Upper medium grade - Investment-grade )
Moody's rating N/A
Detailed description Celgene Corporation was a biopharmaceutical company acquired by Bristol Myers Squibb in 2019, known for its development and commercialization of cancer therapies and other immunology treatments.

Celgene Corp. issued a USD 2,500,000,000 bond (ISIN: US151020AS39, CUSIP: 151020AS3) maturing August 14, 2025, with a 3.875% coupon rate, paying semi-annually, currently trading at 102.101%, minimum purchase 2000, rated A+ by S&P.
DateClean price
09/07/2025102.10%
02/05/2025102.10%
19/02/2025102.10%
07/01/2025102.10%
06/11/2024102.10%
16/09/2024102.10%
07/08/2024100.00%
12/05/2024102.10%
29/08/2023102.76%
05/08/2023102.76%
12/07/2023102.76%
18/06/2023102.76%
25/05/2023102.76%
01/05/2023102.76%
07/04/2023102.76%
14/03/2023102.76%
19/02/2023102.76%
27/01/2023102.76%
04/01/2023102.76%
12/12/2022102.76%
19/11/2022102.76%
27/10/2022102.76%
06/10/2022102.76%
15/09/2022102.76%
25/08/2022102.76%
04/08/2022102.76%
14/07/2022102.76%
23/06/2022102.76%
02/06/2022102.76%
12/05/2022102.76%
21/04/2022102.76%
06/04/2022102.76%
22/03/2022101.99%
07/03/2022102.87%
20/02/2022104.39%
02/02/2022105.36%
18/01/2022104.04%
29/12/2021106.69%
13/12/2021107.26%
26/11/2021107.72%
12/11/2021107.97%
30/10/2021108.02%
16/10/2021108.62%
02/10/2021109.39%
14/09/2021109.80%
29/08/2021109.64%
17/08/2021109.91%
05/08/2021110.18%
24/07/2021110.27%
12/07/2021110.30%
28/06/2021107.90%
14/06/2021110.74%
28/05/2021110.78%
10/05/2021110.62%
20/04/2021110.05%
02/04/2021109.86%
16/03/2021109.90%
01/03/2021110.64%